Neurohumoral regulation of coronary collateral vasomotor tone. 1990

D G Harrison, and F W Sellke, and J E Quillen
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.

As a result of gradual coronary occlusion, coronary collaterals are stimulated to develop. This maturation process involves not only dilatation of the vessel, but the development of new vascular smooth muscle. Experiments have been performed to examine vasomotor characteristics of mature coronary collaterals from dogs 3 to 6 months following ameroid constrictor placement. Studies in Langendorff blood-perfused hearts have shown that transcollateral resistance does not change during either the administration of alpha 1- or alpha 2-adrenergic agonists. Isolated collateral vessels studied as rings in organ chambers do not constrict to either alpha 1- or alpha 2-adrenergic agonists. These studies show that mature collateral vessels are not likely to possess functioning alpha-adrenergic receptors. Subsequent experiments using a cover slip autoradiographic ligand-binding approach have demonstrated a population of beta-adrenergic receptors on mature coronary collaterals. Studies of isolated collaterals have demonstrated beta-adrenoceptor-mediated relaxation that appears due to a population of mixed beta 1- and beta 2-adrenergic receptors. Subsequent studies have demonstrated that mature collateral vessels are hyperresponsive to the vasoconstrictor effects of vasopressin and that concentrations of vasopressin which may be encountered in pathophysiologic conditions can markedly attenuate coronary collateral perfusion. Finally, the microcirculation of the collateral-dependent myocardium develops endothelial cell dysfunction. This results in impaired endothelium-dependent relaxations to adenosine diphosphate and acetylcholine and enhanced vasoconstriction to vasopressin. These alterations of the coronary circulation may have important implications regarding neurohumoral regulation of myocardial perfusion in collateral-dependent myocardium.

UI MeSH Term Description Entries
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D003097 Collateral Circulation Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels. Blood Circulation, Collateral,Circulation, Collateral,Collateral Blood Circulation,Collateral Circulation, Blood,Blood Collateral Circulation,Circulation, Blood Collateral,Circulation, Collateral Blood,Collateral Blood Circulations,Collateral Circulations,Collateral Circulations, Blood
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions
D014667 Vasopressins Antidiuretic hormones released by the NEUROHYPOPHYSIS of all vertebrates (structure varies with species) to regulate water balance and OSMOLARITY. In general, vasopressin is a nonapeptide consisting of a six-amino-acid ring with a cysteine 1 to cysteine 6 disulfide bridge or an octapeptide containing a CYSTINE. All mammals have arginine vasopressin except the pig with a lysine at position 8. Vasopressin, a vasoconstrictor, acts on the KIDNEY COLLECTING DUCTS to increase water reabsorption, increase blood volume and blood pressure. Antidiuretic Hormone,Antidiuretic Hormones,beta-Hypophamine,Pitressin,Vasopressin,Vasopressin (USP),Hormone, Antidiuretic,beta Hypophamine
D018377 Neurotransmitter Agents Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. Nerve Transmitter Substance,Neurohormone,Neurohumor,Neurotransmitter Agent,Nerve Transmitter Substances,Neurohormones,Neurohumors,Neuromodulator,Neuromodulators,Neuroregulator,Neuroregulators,Neurotransmitter,Neurotransmitters,Substances, Nerve Transmitter,Transmitter Substances, Nerve,Substance, Nerve Transmitter,Transmitter Substance, Nerve

Related Publications

D G Harrison, and F W Sellke, and J E Quillen
November 1989, European heart journal,
D G Harrison, and F W Sellke, and J E Quillen
November 1989, European heart journal,
D G Harrison, and F W Sellke, and J E Quillen
December 1991, European heart journal,
D G Harrison, and F W Sellke, and J E Quillen
May 1991, Circulation,
D G Harrison, and F W Sellke, and J E Quillen
May 2012, Annales francaises d'anesthesie et de reanimation,
D G Harrison, and F W Sellke, and J E Quillen
December 1991, Cardiologia (Rome, Italy),
D G Harrison, and F W Sellke, and J E Quillen
November 1989, European heart journal,
D G Harrison, and F W Sellke, and J E Quillen
January 1991, Basic research in cardiology,
D G Harrison, and F W Sellke, and J E Quillen
April 2000, Pharmacology & therapeutics,
D G Harrison, and F W Sellke, and J E Quillen
January 1977, Acta physiologica Academiae Scientiarum Hungaricae,
Copied contents to your clipboard!